Filter Results
:
(255)
Show Results For
-
All HBS Web
(1,023)
- Faculty Publications (255)
Show Results For
-
All HBS Web
(1,023)
- Faculty Publications (255)
Drug →
- March 2006 (Revised July 2006)
- Supplement
Drug Testing in Nigeria (B)
By: Debora L. Spar
Spar, Debora L., and Adam Day. "Drug Testing in Nigeria (B)." Harvard Business School Supplement 706-042, March 2006. (Revised July 2006.)
- February 2006 (Revised August 2006)
- Case
deCODE Genetics: Hunting for Genes to Develop Drugs
By: Debora L. Spar
In 1996, Kari Stefansson launched a new kind of biotechnology company and a whole new way of attacking diseases. Based in Iceland, his firm, deCODE Genetics, plans to identify the individual genetic markers that lead to society's most prevalent diseases. To do so, it...
View Details
Keywords:
Information;
Innovation Strategy;
Genetics;
Ethics;
Health Disorders;
Biotechnology Industry;
Iceland
Spar, Debora L., and Chris Bebenek. "deCODE Genetics: Hunting for Genes to Develop Drugs." Harvard Business School Case 706-040, February 2006. (Revised August 2006.)
- January 2006 (Revised July 2006)
- Case
Drug Testing in Nigeria (A)
By: Debora L. Spar
In 1996, a meningitis epidemic swept across Nigeria. Thousands of children were struck and, lacking appropriate medicine, were liable to die from the disease. Doctors at Pfizer had an antibiotic that could probably save most of these children's lives. The drug was new,...
View Details
Keywords:
Risk and Uncertainty;
Health Pandemics;
Health Testing and Trials;
Developing Countries and Economies;
Pharmaceutical Industry;
Nigeria
Spar, Debora L., and Adam Day. "Drug Testing in Nigeria (A)." Harvard Business School Case 706-033, January 2006. (Revised July 2006.)
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and...
View Details
Keywords:
Health Care and Treatment;
Strategic Planning;
Competition;
Patents;
Innovation and Invention;
Pharmaceutical Industry;
Biotechnology Industry;
United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- November 2005 (Revised November 2005)
- Case
Massachusetts General Hospital and the Enbrel Royalty
By: David S. Scharfstein and Darren R. Smart
Massachusetts General Hospital is considering selling its royalty interest in Enbrel, Amgen's blockbuster drug for the treatment of rheumatoid arthritis. In assessing whether to sell, and at what price, the hospital must determine its value to a potential buyer as well...
View Details
Keywords:
Valuation;
Price;
Investment Return;
Capital;
Value;
Revenue;
Health Care and Treatment;
Health Industry;
Biotechnology Industry;
Massachusetts
Scharfstein, David S., and Darren R. Smart. "Massachusetts General Hospital and the Enbrel Royalty." Harvard Business School Case 206-075, November 2005. (Revised November 2005.)
- August 2005 (Revised December 2006)
- Case
Procter & Gamble: Electronic Data Capture and Clinical Trial Management
By: Robert S. Huckman and Mark J. Cotteleer
Considers whether the management of Procter & Gamble (P&G) Pharmaceuticals should adopt Web-based electronic data capture (EDC) as the default standard for the management of its clinical drug trials. Provides a detailed description of the existing paper-based process...
View Details
Keywords:
Health Testing and Trials;
Internet and the Web;
Information Technology;
Adoption;
Business Processes;
Industry Structures;
Technological Innovation;
Service Operations;
Pharmaceutical Industry;
United States
Huckman, Robert S., and Mark J. Cotteleer. "Procter & Gamble: Electronic Data Capture and Clinical Trial Management." Harvard Business School Case 606-033, August 2005. (Revised December 2006.)
- May 2005 (Revised April 2010)
- Case
GlaxoSmithKline: Reorganizing Drug Discovery (A)
By: Robert S. Huckman and Eli Strick
Describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery...
View Details
Keywords:
Mergers and Acquisitions;
Decision Choices and Conditions;
Operations;
Organizational Structure;
Performance Improvement;
Research and Development;
Pharmaceutical Industry
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (A)." Harvard Business School Case 605-074, May 2005. (Revised April 2010.)
- May 2005
- Supplement
GlaxoSmithKline: Reorganizing Drug Discovery (B)
By: Robert S. Huckman and Eli Strick
Supplements the (A) case.
View Details
Keywords:
Mergers and Acquisitions;
Decisions;
Operations;
Performance;
Research and Development;
Restructuring;
Organizations;
Pharmaceutical Industry
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (B)." Harvard Business School Supplement 605-075, May 2005.
- February 2005 (Revised April 2006)
- Case
Rx Depot: Importing Drugs from Canada
By: Debora L. Spar
In 2002, a handful of entrepreneurs began to ship drugs from Canada into the United States, taking advantage of regulatory and price differentials across the neighboring countries. Using the Internet and a low-cost network of Canadian pharmacies, firms like Rx Depot...
View Details
Keywords:
Courts and Trials;
Entrepreneurship;
Intellectual Property;
Laws and Statutes;
Pharmaceutical Industry;
Canada;
United States
Spar, Debora L., and Adam Day. "Rx Depot: Importing Drugs from Canada." Harvard Business School Case 705-010, February 2005. (Revised April 2006.)
- January 2005 (Revised March 2006)
- Case
Molecular Insight Pharmaceuticals, Inc.
By: Richard G. Hamermesh and Edwin W. Parkinson III
Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing....
View Details
Keywords:
Intellectual Property;
Health Care and Treatment;
Pharmaceutical Industry;
Health Industry
Hamermesh, Richard G., and Edwin W. Parkinson III. "Molecular Insight Pharmaceuticals, Inc." Harvard Business School Case 805-067, January 2005. (Revised March 2006.)
- August 2004 (Revised July 2006)
- Case
PROPECIA TM: Helping Make Hair Loss History
By: Marta Wosinska and Youngme E. Moon
In late 1997, Tom Casola, brand manager for Propecia, debates the best approach to market this breakthrough one-a-day pill for hair loss. This launch would be atypical for a prescription drug because of the key position of the consumer. As a result, the team's...
View Details
Keywords:
Advertising;
Communication Strategy;
Customers;
Marketing Communications;
Marketing Strategy;
Product Launch;
Product;
Performance Effectiveness;
Problems and Challenges;
Quality;
Pharmaceutical Industry
Wosinska, Marta, and Youngme E. Moon. "PROPECIA TM: Helping Make Hair Loss History." Harvard Business School Case 505-035, August 2004. (Revised July 2006.)
- June 2004 (Revised June 2006)
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (A)
By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will...
View Details
Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)
- 2004
- Article
Do Firms Change Capabilities by Hiring New People? A Study of the Adoption of Science-based Drug Discovery
By: Rebecca M. Henderson, Nicola Lacetera and Iain Cockburn
Henderson, Rebecca M., Nicola Lacetera, and Iain Cockburn. "Do Firms Change Capabilities by Hiring New People? A Study of the Adoption of Science-based Drug Discovery." Advances in Strategic Management 21 (2004).
- August 2003 (Revised August 2024)
- Case
Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment
By: Regina E. Herzlinger and John McDonough
Many health care innovations appear successful; but fail. This is the first case in the Innovating Health Care course that investigates how to create successful health care innovations. It is part of the first module in the course. This module focuses on how to...
View Details
Keywords:
Three Pillars;
Industry Analysis;
Health Care and Treatment;
Innovation and Invention;
Innovation and Management;
Medical Specialties;
Health Industry
Herzlinger, Regina E., and John McDonough. "Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment." Harvard Business School Case 304-009, August 2003. (Revised August 2024.)
- June 2003 (Revised May 2006)
- Case
Cipla
By: Rohit Deshpande and Laura Winig
The head of Cipla, a $325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line...
View Details
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the...
View Details
Keywords:
Decision Making;
Health Testing and Trials;
Innovation and Invention;
Markets;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research;
Research and Development;
Complexity;
Biotechnology Industry;
Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- February 2003 (Revised April 2004)
- Case
Pharmaceutical Industry, The: Challenges in the New Century
By: Stephen P. Bradley and James Weber
Provides a broad overview of the numerous internal and external forces that were driving change in the global pharmaceutical industry in 2003. These forces--including downward price pressures, political and social pressures, increased development costs, new...
View Details
Keywords:
Business Model;
Change;
Cost;
Price;
Globalization;
Government and Politics;
Brands and Branding;
Industry Growth;
Society;
Competition;
Consolidation;
Technology;
Pharmaceutical Industry
Bradley, Stephen P., and James Weber. "Pharmaceutical Industry, The: Challenges in the New Century." Harvard Business School Case 703-489, February 2003. (Revised April 2004.)
- September 2002 (Revised August 2003)
- Case
Genzyme's Gaucher Initiative: Global Risk and Responsibility
By: Christopher A. Bartlett and Andrew N. McLean
In Egypt, Genzyme's humanitarian commitment to treat all sufferers of the rare Gaucher disease worldwide first confronts its commercial imperative to recoup the huge investment required to bring the drug Cerezyme to market. Here Tomye Tierney must decide how to balance...
View Details
Keywords:
Moral Sensibility;
Investment;
Emerging Markets;
Negotiation;
Corporate Social Responsibility and Impact;
Business and Government Relations;
Sales;
Commercialization;
Expansion;
Value Creation
Bartlett, Christopher A., and Andrew N. McLean. "Genzyme's Gaucher Initiative: Global Risk and Responsibility." Harvard Business School Case 303-048, September 2002. (Revised August 2003.)
- July 2002
- Article
Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery
By: Stefan Thomke and Walter Kuemmerle
Thomke, Stefan, and Walter Kuemmerle. "Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery." Strategic Management Journal 23, no. 7 (July 2002): 619–635.
- June 2002 (Revised November 2005)
- Case
Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa
By: Debora L. Spar
In the final years of the 20th century, the world was hit by a plague of epidemic proportions--AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought under control through a...
View Details
Keywords:
Patents;
Health Pandemics;
Corporate Social Responsibility and Impact;
Pharmaceutical Industry;
Africa
Spar, Debora L., and Nick Bartlett. "Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa." Harvard Business School Case 702-049, June 2002. (Revised November 2005.)